Accessibility Menu
PAVmed logo

PAVmed(NASDAQ) PAVM

Current Price$4.72
Market Cap$39.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-69%
1 Month+7%
PAVmed last closing stock price
MetricPriceDate
Last closeUSD 5.542026-07-21
PAVmed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.29%USD 5.672026-07-14
1 month+7.36%USD 5.162026-06-18
3 month-40.88%USD 9.372026-04-22
Year to date-16.36%USD 6.622025-12-31
1 year-69.07%USD 17.912025-07-21
3 year-96.38%USD 153.212023-07-21
5 year-99.76%USD 2,276.772021-07-22
Since inception-99.89%USD 5,042.242016-07-28

PAVmed Financials at a Glance

Market Cap

$39.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$85.00K

Net Income (TTM)

-$18.63M

EPS (TTM)

-$37.67

P/E Ratio

-0.15

Dividend

$0.00

Beta (Volatility)

1.35 (Average)

Price

$4.72

Volume

19,224

Open

$5.54

Previous Close

$4.72

Daily Range

$4.40 - $5.65

52-Week Range

$3.85 - $28.44

Estimated Earnings Date

Aug 13, 2026

PAVM News

Foolcom-Featured.png

PAVmed Revenue Jumps 513% in Q2

Motley Fool Markets TeamAug 14, 2025
Women unhappy with body temperature reading

Why PAVmed Stock Plummeted on Wednesday

Eric VolkmanDec 22, 2021
GettyImages-1217056000

Why Shares of PAVmed Were Down This Morning

Jason HawthorneAug 13, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PAVmed

PAVmed creates medical devices that help doctors diagnose and treat common health issues. Its products include tools for early cancer detection and devices for less invasive surgeries. These solutions aim to make procedures easier for both patients and healthcare providers.

Gadgets That Matter: PAVmed’s Main Offerings

  • CarpX: Minimally invasive device for treating carpal tunnel syndrome, used by hand surgeons. (Revenue share not disclosed)
  • EsoCheck & EsoGuard: Tools for early detection of esophageal cancer and Barrett’s Esophagus, targeting gastroenterologists. (Revenue share not disclosed)
  • Veris Cancer Care Platform: Digital health system for remote cancer patient monitoring, sold to cancer care centers. (Primary revenue source in 2025)
  • PortIO: Implantable device for vascular access, used in hospitals for patients needing frequent blood draws or infusions. (Revenue share not disclosed)
  • NextFlo & NextVent: Disposable infusion and ventilator technologies for hospitals and clinics. (Revenue share not disclosed)

Growth Spurts and Bold Moves

  • Launched Lucid Diagnostics in 2018 to commercialize esophageal cancer detection products.
  • Secured new insurance coverage for EsoGuard in New York in 2025.
  • Raised capital through equity offerings at both parent and subsidiary levels in 2025.

Why PAVmed Is a Bit Different

PAVmed uses a flexible structure, funding each product line separately through subsidiaries. Its incubator approach lets it develop multiple devices at once, reducing risk. The company also earns recurring income by managing its Lucid Diagnostics subsidiary.

Five Things You Need to Know

  • Revenue was $6 million in Q2 2025, up 512.9% from Q2 2024.
  • Operating loss was $4.7 million in Q2 2025, down 10.1% from Q2 2024.
  • Cash balance was $4 million as of June 30, 2025, with a $5 million working capital deficit.
  • Management fee income from Lucid was $3.15 million in Q2 2025.
  • Company faces ongoing losses and needs more capital to fund operations.

Bottom Line

PAVmed has evolved by diversifying its product lines and adapting its business model. The company’s structure supports innovation but ongoing losses and funding needs remain key challenges.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

41

CEO

Lishan Aklog, MD

Website

www.pavmed.com

Headquarters

New York City, NY 10165, US

PAVM Financials

Key Financial Metrics (TTM)

Gross Margin

-271.76%

Operating Margin

-28702.35%

Net Income Margin

-21914.12%

Return on Equity

-49.65%

Return on Capital

-46.09%

Return on Assets

-41.01%

Earnings Yield

-6.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$39.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.16M

Volume

19.22K

Avg. Volume

18.34K

Financials (TTM)

Gross Profit

-$231.00K

Operating Income

-$24.40M

EBITDA

-$22.05M

Operating Cash Flow

-$2.62B

Capital Expenditure

-$47.00K

Free Cash Flow

-$2.62B

Cash & ST Invst.

$6.46M

Total Debt

$17.01M

PAVmed Performance Analysis

PAVmed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 377,000-24.6%
20232023-12-31USD 2,452,000550.4%
20242024-12-31USD 2,995,00022.1%
20252025-12-31USD 71,000-97.6%
PAVmed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-25.0%
Q32025-09-30-16.7%
Q42025-12-31940.0%
Q12026-03-31-57.7%
PAVmed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -450.9553.4%
20232023-12-31USD -274.92-39.0%
20242024-12-31USD 14.88N/A
20252025-12-31USD -5.63N/A
PAVmed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-319.5%
Q32025-09-3060.8%
Q42025-12-3172.8%
Q12026-03-31-86.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$22.00K

+175.0%

Gross Profit

-$95.00K

-33.8%

Gross Margin

-4.32%

N/A

Market Cap

$39.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$967.34K

N/A

Employees

41

N/A

Net Income

-$60.00K

-100.3%

EBITDA

-$1.04M

-105.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.46M

+139.3%

Total Debt

$17.01M

+84.1%

Accounts Receivable

$21.00K

+133.3%

Inventory

$0.00

-100.0%

Long Term Debt

$16.42M

+678.3%

Short Term Debt

$588.00K

-91.8%

Return on Assets

-41.01%

N/A

Return on Invested Capital

-58.43%

N/A

Free Cash Flow

-$2.62B

-164991.4%

Operating Cash Flow

-$2.62B

-165617.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IINNInspira Technologies Oxy B.H.N. Ltd.
$1.26-5.97%
ADVBAdvanced Biomed Inc. Common Stock
$12.25+73.02%
APVOAptevo Therapeutics Inc.
$4.45+0.68%
BNRBurning Rock Biotech Limited
$9.14-3.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
PATHUiPath
$10.70-0.11%
NOKNokia
$10.28-0.03%
SOFISoFi Technologies
$17.07-0.03%
INTCIntel
$102.62-0.03%

Questions About PAVM

What is the current price of PAVmed?

PAVmed is trading at $4.72 per share.

What is the 52-week range for PAVmed?

Over the past 52 weeks, PAVmed has traded between $3.85 and $28.44.

How much debt does PAVmed have?

As of the most recent reporting period, PAVmed reported total debt of $17.01M.

How much cash does PAVmed have on hand?

PAVmed reported $6.46M in cash and cash equivalents in its most recent financial results.

What is PAVmed’s dividend yield?

PAVmed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services